Zoetis Inc. (NYSE:ZTS) is a leading global animal health company that develops and manufactures medicines and vaccines for pets and livestock. The company is set to release its third-quarter 2025 earnings on November 4, 2025. Wall Street anticipates earnings per share (EPS) of $1.62 and revenue of approximately $2.41 billion.
Zoetis is expected to surpass these estimates, driven by strong demand for its companion animal products like Simparica Trio and Apoquel. The Zacks Consensus Estimate aligns with Wall Street's projections, suggesting robust performance in the companion animal segment. However, the company may face challenges in its livestock product revenue due to the divestiture of certain assets.
The company's diverse portfolio continues to support its financial health. Zoetis is projected to report a year-over-year increase in earnings, attributed to higher revenues for the quarter ending September 2025. This potential growth could positively impact the stock price, although any shortfall in expectations might lead to a decline.
Zoetis' financial metrics provide insight into its market valuation. With a price-to-earnings (P/E) ratio of 24.60, investors are willing to pay $24.60 for every dollar of earnings. The price-to-sales ratio of 6.82 and enterprise value to sales ratio of 7.39 reflect the market's valuation of its revenue and sales.
The company's financial stability is further highlighted by its debt-to-equity ratio of 1.36, indicating a balanced use of debt and equity in financing. A current ratio of 1.76 suggests Zoetis can comfortably cover its short-term liabilities. The earnings yield of 4.07% offers a return on investment based on earnings, showcasing the company's profitability.
